Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Structures and people to govern Dementias Platform UK

Dementias Platform UK (DPUK) is a multi-million pound public-private partnership which launched in 2014. DPUK is directed by Professor John Gallacher (University of Oxford) and is supported by an executive team of ten other representatives from our academic and industry partners.

Governance structure

 

A steering group of 20 senior scientists, many of whom lead projects across the platform, influence the scientific direction of the project by making recommendations to the executive team.

The director and executive team, in turn, report to an MRC-appointed oversight board twice a year. The board oversee DPUK activity and advise on opportunities or changes for the project. Its members are UK and international experts in the field of dementia.

DPUK is supported by four international advisors, all experts in the field of dementia and neurodegenerative disease.

Funding to enable the platform’s work

Dementias Platform UK has received £53 million from the UK Medical Research Council. Each of our industry partners also makes a contribution – financial or in-kind – to enable the work of the platform.

 The amount of additional funding for dementia research that we have attracted can be seen in the table below.

 

£ m

Funder and project

Principal Investigator

University

Funding type

16

MRC-industry core funding

John Gallacher

Cardiff

Core

37

MRC clinical research infrastructure:
Imaging network
Stem cells network
Informatics network

Paul Matthews 
Richard Wade-Martins
Simon Lovestone

Imperial College London, 

Oxford

Oxford

Core

1

MRC: Imaging partnership

Karl Herholz

Manchester

Supported

1

MRC: Stem Cells partnership

Siddharthan Chandran

Edinburgh

Supported

0.3

Alzheimer's Research UK (ARUK): Imaging

David Thomas

University College London

Supported

2

Stroke Association: Vascular Risk

Joanna Wardlaw

Edinburgh

Supported

0.5

Janssen and Alzheimer's Research UK (ARUK): Synaptic Health

James Rowe

Cambridge

Supported

60

Innovative Medicines Initiative (IMI): European Prevention of Alzheimer's Dementia Consortium (EPAD)

Craig Ritchie

Edinburgh

Enabled

7

MRC National Institute for Health Research (NIHR): Deep and Frequent Phenotyping

Simon Lovestone

Oxford

Enabled

3.4

Innovative Medicines Initiative (IMI): Real World Outcomes Across the Alzheimer's Disease Spectrum (ROADS)

John Gallacher

Oxford

Enabled

1.1

MRC: UK7T partnership 

James Rowe

Cambridge

Enabled

7

MRC clinical research infrastructure: UK7T

James Rowe

Cambridge

Enabled

0.1

MRC: Korea

Chi-Hun Kim

Oxford

Enabled

Research income generated: £83.4 m (157% of core funding)